The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2018 | CAR T-cell therapy for refractory multiple myeloma
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the results of the first-in-human CRB-401 study (NCT02658929) investigating the use of idecabtagene vicleucel (formerly bb2121) anti-BCMA CAR T-cells in refractory multiple myeloma (MM). Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Dr Munshi remarks that while CAR T-cell therapy may be expensive, the cost of current treatments for refractory MM is not insignificant. However, given that the efficacy has shown to be exceptional, and side effects such as cytokine release syndrome occur to a lesser degree when treating MM compared with leukemia or lymphoma, CAR-T cell therapy looks to be a promising alternative option for refractory MM.
